Mesoblast Limited - American Depositary Shares (MESO)
MESO moved a median of -0.47% 30 minutes after news, and +0.17% by the close. How MESO actually reacts to news — the realized, point-in-time move the market made, measured across 108 labeled events over the last three years with zero look-ahead.
MESO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 108 |
| 30-min | -0.47% | 42% | 108 |
| 60-min | -0.08% | 48% | 108 |
| to close | +0.17% | 52% | 108 |
| Middle 50% of MESO reactions | -1.42% to +0.96% |
|---|---|
| Median reaction (30-min) | -0.47% |
| Measured reactions | 108 |
Half of all Mesoblast Limited - American Depositary Shares news events land between -1.42% and +0.96% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MESO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 23 | -0.15% | 39% | +0.36% |
| Analyst downgrades | 10 | -1.20% | 40% | +1.43% |
| Rating reiterations | 15 | -1.01% | 27% | -0.69% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MESO ranks against every other measured name →
That’s how MESO usually reacts — get an email when it moves on news →Email me when MESO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MESO's baseline. Nothing else.
Recent MESO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K MESOBLAST LTD For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | -0.43% | -4.53% | |
| Form 6-K MESOBLAST LTD For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | +2.88% | |
| Form 6-K MESOBLAST LTD For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | -0.89% | -2.56% | |
| Form 6-K MESOBLAST LTD For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +0.59% | +2.18% | |
| Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product | Press release | GlobeNewswire | +0.59% | +2.18% | |
| Form 20-F MESOBLAST LTD For: Jun 30 | SEC filing · Form 20-F | SEC EDGAR | -2.23% | +2.02% | |
| Form 6-K MESOBLAST LTD For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | -2.23% | +2.02% | |
| Mesoblast Reports Substantial Revenue Growth to US$120M | Press release | GlobeNewswire | -2.23% | +2.02% | |
| Form 6-K MESOBLAST LTD For: Aug 25 | SEC filing · Form 6-K | SEC EDGAR | +0.54% | +2.75% | |
| Form 6-K MESOBLAST LTD For: Aug 24 | SEC filing · Form 6-K | SEC EDGAR | -0.06% | +0.36% | |
| Mesoblast Financial Results and Corporate Update Webcast | Press release | GlobeNewswire | -1.31% | -0.95% | |
| Form 6-K MESOBLAST LTD For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +0.47% | -1.42% | |
| Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain | Press release | GlobeNewswire | -0.87% | -1.10% | |
| Form 6-K MESOBLAST LTD For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | +0.70% | +1.61% | |
| Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch | Press release | GlobeNewswire | +0.70% | +1.61% | |
| Form 6-K MESOBLAST LTD For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | -1.71% | +0.06% | |
| Form 6-K MESOBLAST LTD For: Jul 14 | SEC filing · Form 6-K | SEC EDGAR | +2.56% | +3.99% | |
| Form 6-K MESOBLAST LTD For: Jul 14 | SEC filing · Form 6-K | SEC EDGAR | -0.42% | +1.46% | |
| Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain | Press release | GlobeNewswire | -0.42% | +1.46% | |
| Form 6-K MESOBLAST LTD For: Jul 10 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | -0.26% | |
| Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 | Press release | GlobeNewswire | +0.16% | -0.26% | |
| Form 6-K MESOBLAST LTD For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.64% | |
| Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs | Press release | GlobeNewswire | +0.00% | +0.64% | |
| Form 6-K MESOBLAST LTD For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | +0.07% | -0.07% | |
| Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility | Press release | GlobeNewswire | +0.07% | -0.07% | |
| Form 6-K MESOBLAST LTD For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | +0.79% | -1.36% | |
| Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million | Press release | GlobeNewswire | +0.20% | +2.08% | |
| Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain | Press release | GlobeNewswire | -0.22% | -0.77% | |
| Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products | Press release | GlobeNewswire | +1.23% | +1.74% | |
| Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION | Press release | GlobeNewswire | -2.46% | -1.01% | |
| Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation | Press release | GlobeNewswire | +0.00% | -2.79% | |
| Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +0.00% | -2.79% | |
| Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter | Press release | GlobeNewswire | -0.36% | -1.41% | |
| Mesoblast to Host R&D Day on April 8, 2026 | Press release | GlobeNewswire | -0.23% | -0.14% | |
| Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast | Press release | GlobeNewswire | -0.42% | -1.63% | |
| Ryoncil® Profits Underpinning Substantial Growth Pipeline | Press release | GlobeNewswire | -0.63% | +0.32% | |
| Mesoblast Financial Results and Corporate Update Webcast | Press release | GlobeNewswire | +0.27% | -0.06% | |
| High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD | Press release | GlobeNewswire | -1.30% | -4.20% | |
| Ryoncil® Net Revenues Increase for the Quarter to US$30M | Press release | GlobeNewswire | +0.82% | -2.07% | |
| Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment | Press release | GlobeNewswire | +0.51% | +2.08% | |
| FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy | Press release | GlobeNewswire | -1.40% | -1.58% | |
| Ryoncil® Sales Increase 60% in December Quarter to US$35.1M | Press release | GlobeNewswire | +0.99% | +4.17% | |
| Mesoblast Announces Changes to Board of Directors' Leadership Roles | Press release | GlobeNewswire | +0.00% | -0.71% | |
| Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line | Press release | GlobeNewswire | +0.00% | -2.47% | |
| Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD | Press release | GlobeNewswire | -0.22% | -2.01% | |
| Mesoblast Participation at Piper Sandler Conference | Press release | GlobeNewswire | -0.24% | +1.24% | |
| Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue | Press release | GlobeNewswire | -0.43% | -0.80% | |
| Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids | Press release | GlobeNewswire | +0.65% | +4.42% | |
| James M. O’Brien Appointed Chief Financial Officer at Mesoblast | Press release | GlobeNewswire | +1.75% | +0.27% | |
| Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation | Press release | GlobeNewswire | +0.62% | +0.06% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MESO section they belong to.
Where else MESO is measured.
MESO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mirati Therapeutics, Inc. (MRTX) | 109 | +0.11% | 81% |
| Avinger, Inc. (AVGR) | 108 | -0.24% | 29% |
| WELLNESS CENTER USA INC (WCUI) | 108 | 0.00% | 24% |
| BAYER AG S/ADR (BAYRY) | 106 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Mesoblast Limited - American Depositary Shares's median reaction calculated?
Every labeled MESO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 108 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of MESO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MESO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.